石药集团 20260302 摘要 石药集团创新管线进入兑现期，重点布局肿瘤、减肥/代谢及小核酸领域， 与阿斯利康达成 185 亿美金合作，首付款 12 亿美金，强化其全球化交 易能力和里程碑兑现预期。 石药集团在小分子、ADC 及生物药方向均有深入布局，多个项目处于全 球研发前列，部分具备 first-in-class 属性，EGFR ADC、CD47/CD20 双抗等展现 Best-in-class 潜力。2026 年将迎来早期临床数据密集读出 窗口。 EGFR ADC (6,010) 在 EGFR 突变非小细胞肺癌及后线适应症上体现出 潜在 Best-in-class 特征，并具备广谱 ADC 属性，覆盖多种实体瘤。公 司正探索前线联合治疗，2026 年或有联合治疗数据读出。 CD47/CD20 双特异性融合蛋白 (601) 在血液瘤中显示出较好疗效与安 全性，并有望拓展至 B 细胞相关自身免疫性疾病领域。 PD-1/L15 融合蛋白 (108) 主要针对尿路上皮癌方向的非肌层浸润性膀 胱癌，聚焦 BCG 不响应患者人群，预计 2026 年将发布部分数据。 与阿斯利康在 GLP-1 方向的合作是平台型合作 ...

智通财经APP获悉，海通国际发布研报称，石药集团(01093)的主营业务收入、利润已经触底，2026年有 望回到上升周期，2027年开始受益于肿瘤和代谢创新产品放量，成药收入有望提速。石药集团当前潜在 临床里程碑收入达58亿美元（约人民币406亿元），有望在未来3-5年陆续增厚公司利润。该行认为首付 款和里程碑收入将为公司带来可持续的经常性收益，并上调了2027年后的授权收入预测。该行使用现金 流折现（DCF）模型及FY27-FY35的现金流进行估值。基于WACC 7.9%，永续增长率2.5%（均不 变），对应目标价13.07港元，并维持"优于大市"评级。 海通国际主要观点如下： 研发能力多次获得认可，该行看好常态化里程碑收入夯实公司基本面 近两年来石药集团实现7笔对外合作交易，涉及首付款总额17.1亿美元，潜在里程碑总额超300亿美元。 公司与全球顶尖药企阿斯利康三度达成合作，彰显石药集团研发平台在全球范围的影响力与价值。该行 认为，加总近60亿美元的潜在研发里程碑将会在未来3-5年陆续增厚石药集团的利润，成为公司常态化 收入的重要组成部分。该行看好石药集团可以持续以销售里程碑和销售净额分成的方式在整个药品 ...

21世纪经济报道记者韩利明 小核酸领域再迎重磅BD（商务拓展）交易。 2月23日晚间，科创板创新药企前沿生物（688221.SH）公告，已与葛兰素史克（GSK）达成一项独家授权许可协议，GSK获得公司 两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。 协议显示，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。前沿生物将负责其中一款产品在中 国的I期临床试验推进，并完成另一款产品的IND支持性研究。 作为交易对价，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并在两个项目中累计获得最高9.5亿美元的基于成 功开发、监管及商业化里程碑的付款，同时享有两款产品全球净销售额的分级特许权使用费。 有业内人士向21世纪经济报道记者指出，当前全球小核酸领域交易持续升温，这笔近10亿美元合作有望改善前沿生物现金流、支撑 研发与平台升级，成为其2020年上市以来持续亏损背景下的重要发展拐点，"不过相较于确定性首付款，后续里程碑兑现情况需持续 跟踪"。 受此利好消息提振，作为春节假期后的首个交易日，前沿生物股价在2月24日早盘高开，截至午间休盘报24.5 ...

价格表现：近7日（2026年2月16日至2月20日），百心安-B股价区间下跌3.20%，其中2月16日收盘报 5.50港元（单日跌2.14%），2月20日收盘报5.44港元（单日跌1.09%）。股价波动受港股大盘走弱（恒 生指数同期跌2.83%）及医疗板块调整影响。 股票近期走势 经济观察网 华鑫证券在2026年2月15日发布的医药行业周报中，将百心安-B（02185.HK）列为医疗器械 领域高值耗材出口突破的值得关注标的，反映出机构对其在海外市场拓展潜力的认可。该报告同时指 出，医药行业整体聚焦原料药供给变化、GLP-1减重领域合作及小核酸技术突破，百心安-B作为医疗设 备企业，可能间接受益于行业创新趋势。 技术指标：截至2月20日，股价低于5日、10日及20日均线，MACD柱状图为负值，显示短期弱势；但布 林带下轨（5.256港元）提供部分支撑，KDJ指标中J线降至29.5，接近超卖区域。 机构观点 资金流向：2月20日散户资金净流入80,403港元，主力资金无显著活动，换手率仅0.02%，市场交投清 淡。 华鑫证券在2026年2月15日发布的医药行业周报中，将百心安-B（02185.HK）列为医疗器械领 ...

Group 1 - The core point of the article is that Chengdu XianDao (688222) plans to invest 24 million yuan in Chengdu XianYan Biological Technology Co., Ltd. at a pre-investment valuation of 450 million yuan [2] - Chengdu XianYan is a subsidiary and related party of Chengdu XianDao, with a registered capital of 17.2408 million yuan, and aims to raise no more than 150 million yuan for its development [2] - The company has established an innovative technology system including novel small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology, focusing on chronic disease treatment [2] Group 2 - The investment will increase Chengdu XianDao's stake in Chengdu XianYan, which currently holds 23.2% of the equity, with the final ownership percentage to be determined based on the total financing amount and the new registered capital [2]

国泰海通证券发布研报称，政策落地、全球并购回暖及积极临床数据共同提振创新药行业风险偏好。 2026年，肿瘤领域PD-1/VEGF双抗和Pan-RAS疗法迎来关键数据验证；减重代谢市场关注自费市场拓展 及小核酸技术升级；自免领域聚焦新一代抗体平台POC数据；中枢神经系统(CNS)领域则围绕Aβ单抗治 疗前移与递送技术突破。 国泰海通证券主要观点如下： 自免：MNC大单品集中度风险凸显，2026年POC数据读出带来结构性机会 MNC自免业务对少数重磅单品依赖度较高，专利周期与竞争加剧背景下的收入集中风险逐步显现。增 量机会主要来自两条路径：其一，新一代抗体平台(双抗/多抗、B细胞耗竭等)将在2026年迎来密集POC 数据读出，或催生新一轮BD与资产重估；其二，口服化趋势逐步清晰，自免疾病长期用药属性决定了 口服剂型在依从性与差异化竞争上的天然优势，BTK、TYK2/JAK、口服PROTAC、口服环肽、PDE4等 多技术路线值得持续跟踪。 CNS：核心主线是Aβ单抗治疗前移，跨BBB技术放大长期空间 CNS领域的核心投资主线仍聚焦于Aβ单抗治疗从早期症状人群向临床前(preclinic alAD)前移，礼来 Don ...

Group 1 - The "small nucleic acid" sector is gaining significant attention and investment, moving from laboratory research to the forefront of the industry [1] - Traditional drugs struggle with over 80% of disease-related targets being "undruggable," while small nucleic acid drugs offer a new approach by targeting the "blueprints" of disease-causing genes [2][3] - Small nucleic acid drugs, such as ASO and siRNA, can silence or regulate the expression of pathogenic genes, providing new treatment pathways for diseases like spinal muscular atrophy [4] Group 2 - The delivery system is a critical bottleneck for the development of small nucleic acid drugs, with recent advancements enabling targeting beyond the liver to other organs [5] - The FDA has approved 19 small nucleic acid drugs globally, with ASO and siRNA making up 38% and 32% of the development focus, respectively [5] - The pipeline for siRNA drugs is expanding into chronic diseases and CNS disorders, with significant applications in metabolic and cardiovascular diseases [6] Group 3 - The global market for small nucleic acid drugs is projected to grow from $2.7 billion in 2019 to $5.7 billion in 2024, with a compound annual growth rate (CAGR) of 16.2% [8] - The siRNA market share is expected to increase significantly, from $200 million in 2019 (7% share) to $2.4 billion in 2024 (44.5% share) [9] - Chinese companies are increasingly recognized for their innovation in small nucleic acids, with significant licensing deals and collaborations, marking a shift from following to competing in the global market [13] Group 4 - Notable acquisitions, such as Novartis's $12 billion purchase of Avidity, highlight the strategic importance of small nucleic acid platforms in drug delivery [8] - Companies like Be Better Med and Frontier Bio are developing diverse pipelines targeting various diseases, including hypertension and metabolic disorders [16][17] - The rise of small nucleic acids signifies a paradigm shift in drug discovery, moving from protein-based approaches to rational design based on genetic sequences [19]

Group 1: Consumer Sector Overview - Despite macroeconomic uncertainties, the consumer sector is undergoing a deep adjustment phase, with leading companies showing structural resilience and positive signals emerging in several sub-sectors [1] - The investment logic in the consumer sector has shifted from Beta-driven to Alpha-exploration, focusing on leading companies with scale barriers, brand influence, and operational efficiency [1] Group 2: Alcohol Industry - The overall sales of the liquor industry are experiencing a double-digit decline, but Kweichow Moutai is outperforming market expectations, with significant pre-holiday demand and double-digit growth in several key markets [2] - Moutai's traditional channel shipment progress is at 25%, with historical low inventory levels, leading to a steady price recovery to nearly 1700 yuan, confirming the price bottom [2] - The trend of increasing industry concentration continues, with leading brands expected to achieve year-on-year growth despite macroeconomic pressures [2] Group 3: Snack Industry - The bulk snack channel is rapidly replacing traditional retail formats, with a market size exceeding 129.7 billion yuan and a compound annual growth rate of 77.9% from 2019 to 2024 [3] - The market is highly concentrated, with leading brands "Mingming Hen Mang" and "Wancheng" holding over 75% market share, and "Mingming Hen Mang" alone accounting for approximately 43% [3] - The operational efficiency of leading companies is expected to enhance market penetration, benefiting from scale effects and further increasing industry concentration [3] Group 4: Pharmaceutical Industry - The investment opportunities in the pharmaceutical sector are increasingly structural, with the innovative drug industry chain remaining a core focus, particularly in areas like immunotherapy and small nucleic acid technology [4] - The CXO sector is experiencing a steady recovery, with improved overseas biotech financing conditions and a structural rebound in domestic CRO demand [4] - The medical device sector is expected to benefit from recovering hospital demand and improving inventory cycles, with domestic companies likely to gain market share due to expanding procurement policies [5] Group 5: Agriculture and Livestock - The pig farming industry is undergoing capacity reduction, with the number of breeding sows decreasing to 39.61 million by the end of 2025, leading to a potential price recovery supported by seasonal demand [7] - The poultry farming sector is facing tight supply due to previous overseas breeding restrictions, while the yellow feather chicken market is entering a growth phase with low historical breeding costs [7] - The planting sector is benefiting from agricultural cycle rotations and policy support, with the domestic transgenic corn industry expected to expand, favoring leading seed companies with strong R&D capabilities [7]

Core Insights - The report from Huazhong Securities highlights breakthroughs in small nucleic acid technology and its application in rare diseases, cardiovascular diseases, significant metabolic areas, CNS, and even oncology, indicating a growing investment opportunity in the siRNA sector [1] Group 1: Key Events - Novartis plans a major investment in small nucleic acids by 2025, with three business development (BD) transactions and a $12 billion acquisition, reflecting significant industry impact [1] - Novartis's product Inclisiran achieved $555 million in sales in the first half of 2025, a 66% year-on-year increase, and its Swiss base received an $80 million investment to expand siRNA production [1] - Domestic company Bewang Pharmaceutical's $5 billion out-licensing deal with Novartis sets a record for non-oncology BD transaction amounts [1] Group 2: Technological Advancements - Delivery technology is advancing from liver-targeting to cross-brain and lung-targeting, indicating breakthroughs in extrahepatic targeting [2] - The range of indications is expanding from rare diseases and cardiovascular conditions to significant metabolic areas, CNS, and oncology [2] Group 3: Drug Target Layout - Established targets include Inclisiran (PCSK9), which opened the siRNA application in cardiovascular fields, with emerging targets like INHBE and ALK7 showing promising initial data in obesity [3] - New targets such as ApoC3, Lpa, and ANGPTL3 are becoming standard for drug companies in lipid regulation treatments, while AGT and FXI are deepening applications in hypertension and thrombotic diseases [3] - The siRNA application scope is continuously expanding with new developments in diseases related to complement and kidney conditions [3]

Core Viewpoint - China National Pharmaceutical Group (stock code: 01177.HK) announced the acquisition of Hegia Biotech for a total consideration of 1.2 billion RMB, marking a strategic move into the siRNA innovation drug sector [1][7] Group 1: Acquisition Details - The acquisition will be financed through a combination of cash and equity, with approximately 1.1 billion RMB paid in cash and the remaining 97 million RMB through the issuance of new shares at HKD 6.66 per share [1][7] - Following the transaction, Hegia will become a wholly-owned subsidiary of China National Pharmaceutical Group, integrating its R&D pipeline and technology platform into the company's chronic disease treatment strategy [1][7] Group 2: Hegia Biotech Overview - Founded in 2018, Hegia has emerged as a "dark horse" in the domestic siRNA field, leveraging its proprietary multi-organ targeted delivery technology [2][8] - Hegia's key advantages include a clinically validated liver delivery platform capable of "once-a-year" dosing, a dual-chain conjugation technology platform, and a neural delivery platform [2][8] - Hegia currently has four clinical-stage projects and over 20 preclinical projects, with the most advanced being Kylo-11, which targets lipoprotein(a) and has initiated a multi-center Phase II clinical trial in October 2025 [2][8] Group 3: Market Context and Valuation - The global market for siRNA is projected to reach USD 15 billion, with no approved targeted drugs currently available, indicating a pressing clinical need [2][8] - The acquisition valuation of 1.2 billion RMB corresponds to an 18.75x market cap/research spending ratio based on Hegia's R&D expenditure for 2024, which is considered low compared to similar overseas companies [3][9] - The acquisition is seen as a strategic move to fill gaps in China National Pharmaceutical Group's cardiovascular treatment portfolio and create synergies with existing chronic disease pipelines [2][3][9] Group 4: Financial Strength and Industry Trends - As of June 2025, China National Pharmaceutical Group had over 30 billion RMB in cash and liquid assets, providing a solid foundation for ongoing investments in innovative drugs [4][10] - The siRNA sector has become a focal point for global pharmaceutical companies, with a total transaction volume of USD 35 billion in 2025, reflecting a 40% year-on-year growth [4][10] - The competitive landscape includes established international players like Alnylam, which has a market cap exceeding USD 50 billion, and domestic companies like Reebio, which recently went public [4][10] Group 5: Challenges and Future Prospects - The acquisition faces challenges, including Hegia's core pipelines being in early to mid-clinical stages, requiring lengthy R&D and approval processes [5][12] - Hegia's external delivery technologies have not yet been clinically validated, and scaling production of siRNA drugs remains an industry bottleneck [5][12] - Despite these challenges, the acquisition's synergy potential is significant, as China National Pharmaceutical Group's industrial capabilities could help Hegia navigate the "valley of death" in biotech [6][12]